PROCEPT BioRobotics Securities Fraud Class Action
Analysis based on 7 articles · First reported Aug 28, 2026 · Last updated Sep 02, 2026
The disclosure of excess inventory and missed guidance triggered an 18% stock decline, reflecting investor concerns about demand and revenue quality. The securities class action adds legal and reputational risk, potentially leading to financial penalties and further stock volatility.
PROCEPT BioRobotics Corporation faces a securities class action lawsuit filed by the Operating Engineers Construction Industry and Miscellaneous Pension Fund in the United States — United States District Court for the Northern District of California. The lawsuit alleges that PROCEPT and certain executives failed to disclose material information during the Class Period (February 28, 2024 to February 25, 2026), violating federal securities laws. On February 25, 2026, PROCEPT announced Q4 and full-year 2025 earnings, revealing that U.S. handpiece sales had materially exceeded procedures every quarter since Q1 2023, leading to cumulative excess field inventory of over 10,000 units. Consequently, quarterly handpiece unit sales declined nearly 30% from 13,225 to 9,400 units, causing the company to miss annual revenue guidance by tens of millions of dollars. Following the announcement, PROCEPT's stock fell over 18% from $27.84 to $22.69 per share over two days. Kahn Swick & Foti, LLC, led by Lewis Kahn and Charles Foti, is reminding investors of the September 22, 2026 deadline to file lead plaintiff applications.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard